Loading clinical trials...
Loading clinical trials...
Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment in Patients Who Did Not Tolerate Other 20% Subcutaneous Immunoglobulin Product(s)
Conditions
Interventions
16,5% Cutaquig
Locations
1
Canada
The Ottawa Hospital, General Campus
Ottawa, Ontario, Canada
Start Date
September 19, 2018
Primary Completion Date
August 31, 2021
Completion Date
August 31, 2021
Last Updated
March 4, 2020
NCT05755035
NCT06955793
NCT06089122
NCT06150833
NCT01218438
NCT01175213
Lead Sponsor
Ottawa Hospital Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions